Keywords: first, data, bayer, oral, raf, kinase, inhibitor

First data on Bayer's oral Raf kinase inhibitor

Article | 27 March 2001

Print This

Onyx Pharmaceuticals and Bayer have reported Phase I clinical resultswith BAY-43-9006, claimed to be the first orally-active Raf kinase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in